Showing results (521-530 of 561) with videos related to

Sort By:
Pageof 57
The Lancet. Oncology|March 20, 2025
Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortiumAmar U Kishan, Yilun Sun, Alison C Tree, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 6, 2026
Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate CancerC T A Parker, H-C Huang, E Grist, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 9, 2020
Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical controlRebecca G Levin-Epstein, Naomi Y Jiang, Xiaoyan Wang, et al.
JAMA Oncology|March 28, 2020
Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate CancerRobert T Dess, Yilun Sun, William C Jackson, et al.
Lancet (London, England)|March 1, 2026
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysisAmar U Kishan, Yilun Sun, Christopher C Parker, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 15, 2020
Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patientsRebecca Levin-Epstein, Ryan R Cook, J Karen Wong, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 10, 2025
Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In OncologyDaniel E Spratt, Sandy Srinivas, Nabil Adra, et al.
European Urology|July 28, 2026
Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysisAmar U Kishan, Yilun Sun, Christopher C Parker, et al.
Cancer|December 1, 2024
Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024Alan H Bryce, Neeraj Agarwal, Himisha Beltran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2021
BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity ProgramDae-Hwan Kim, Duanchen Sun, William K Storck, et al.
Pageof 57